Drug Search Results
More Filters [+]

BTH-1704

Alternative Names: bth-1704, bth1704, bth 1704
Latest Update: 2015-05-01
Latest Update Note: Clinical Trial Update

Product Description

BTH1704 (BTH) is a humanized monoclonal antibody (MAb) targeting aberrantly glycosylated MUC1. (Sourced from: https://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.tps493)

Mechanisms of Action: IgG1 Analogue

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: University of Illinois at Chicago
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BTH-1704

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Pancreatic Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PM-01

P1

Terminated

Pancreatic Cancer

2015-04-01

Recent News Events

Date

Type

Title